Vaginal Dryness

4

Review clinical trials related to Vaginal Dryness. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

VEDA Study (DHEA vs Estradiol)

This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.

Participants needed: 324
Trial details
Age: 40-90Biological sex: FemaleType: InterventionalSponsor: University of ArizonaUpdated: Jun 17, 2026
Eligibility criteria

Peri- or post-menopausal status [+5]

Use of systemic hormone therapy within the last 6 months [+4]

Status: Recruiting

Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women

This study aims to explore the positive effect of a dietary supplement composed of wheat polar lipids on vaginal dryness in healthy postmenopausal women

Participants needed: 110
Trial details
Age: 45-65Biological sex: FemaleType: InterventionalSponsor: SeppicUpdated: Apr 23, 2026Locations: 1
Eligibility criteria

Healthy woman, aged of 45 to 65 years (inclusive) [+6]

Use of systemic hormonal therapy within the past 3 months [+9]

Status: Recruiting

Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.

The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.

Participants needed: 80
Trial details
Age: 40-70Biological sex: FemaleType: InterventionalSponsor: Mucosa Innovations, S.L.Updated: Mar 30, 2026Locations: 1
Eligibility criteria

Patient has to have at least one symptom of GSM or suffer from symptoms related... [+4]

Patients that do not want to fill the questionnaire, especially the questions th... [+12]

Status: Recruiting

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients

This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer. Patients will be randomly assigned to one of two parallel treatment groups until the six-month assessment: The first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators. The second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.

Participants needed: 75
Trial details
Age: 40+Biological sex: FemaleType: InterventionalSponsor: Centre Oscar LambretUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

Patient over 40 years [+5]

Ongoing urinary tract infection [+8]